Bellicum Pharmaceuticals Inc (BLCM) Return on Investment ROI from the third quarter of 2023 to third quarter of 2022 and for the year 2023, average high and low, overall ranking from Sep 30 2023 to Sep 30 2022 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Bellicum Pharmaceuticals Inc   (BLCM)


Bellicum Pharmaceuticals Inc's ROI from its third quarter of 2023 to the third quarter of 2022 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Bellicum Pharmaceuticals Inc's ROI in the third quarter of 2023?
Bellicum Pharmaceuticals Inc achieved a return on average invested assets (ROI) of 19.61 % in its third quarter of 2023, this is above BLCM's average return on investment of -116.21%.
Bellicum Pharmaceuticals Inc invested over the 12 months ending in its third quarter of 2023 $13 million

ROI has improved compared to -19.95% in the second quarter of 2023, due to net income growth.

Within the Healthcare sector 48 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Sep 30 2023 quarter, so far to 340, from total ROI ranking in the second quarter of 2023 at 3457.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Sep 30 2023)
III. Quarter		 (Jun 30 2023)
II. Quarter		 (Mar 31 2023)
I. Quarter		 (Dec 31 2022)
IV. Quarter		 (Sep 30 2022)
III. Quarter
Y / Y Investment Change TTM -62.55 % -33.25 % 14.97 % 107.56 % 364.97 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 7 9 17 20 31
Return On Investment (TTM) 19.61 % -19.95 % -2.01 % -0.01 % -44.67 %
BLCM's Overall Ranking # 340 # 3457 # 2541 # 2868 # 0
Seq. Investment Change TTM -31.59 % -23.19 % -15.31 % -15.84 % 21.94 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions 3 -4 -1 0 -16

BLCM Company Profile >> Back to BLCM Roi Comparisons >> See Annual BLCM Return On Investment



Return On Investment BLCM's Ranking
Within: No.
Industry # 22
Sector # 49
Overall # 340

Return On Investment Statistics
High Average Low
391.58 %
-116.21 %
-1419.81 %
(Jun 30 2021)   (Mar 31 2021)







Financial Statements
Bellicum Pharmaceuticals Inc's III. Quarter Investments $ 7 Millions BLCM's Balance sheet
Bellicum Pharmaceuticals Inc's III. Quarter Income $ -1 Millions Quarterly BLCM's Income Statement
BLCM's Income by Division See BLCM's Income by Division


BLCM Annual Return On Investment (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020		 (Dec 31 2019)
2019		 (Dec 31 2018)
2018
Total Investments in Millions 20 42 16 21 106
Y / Y Investment Growth -52.74 % 173.06 % -25.89 % -80.16 % -14.33 %
Net Income in Millions 0 -10 -8 -112 -98
Y / Y Net Income Growth - - - - -
Annual Return On Investment -0.01 % -22.87 % -49.69 % -536.42 % -92.75 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
BLCM's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for BLCM's Competitors
Subscribers only: Roi for Bellicum Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Investment for BLCM's Customers

Other Ratios
BLCM's Roa BLCM's Inventory Turnover Ratio BLCM's Growth Rates BLCM's Dividend Statistics
BLCM's Profitability Ratios BLCM's Asset Turnover Ratio BLCM's Dividend Growth
BLCM's Roe BLCM's Valuation Ratios BLCM's Financial Strength Ratios BLCM's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2023, within Healthcare Sector ROI
Cv Sciences Inc   51.59 %
Elite Pharmaceuticals Inc   47.02 %
Gyre Therapeutics Inc   45.47 %
Star Equity Holdings Inc   44.42 %
Idexx Laboratories Inc  43.85 %
Entera Bio Ltd   41.70 %
Zymeworks Inc   39.50 %
Medpace Holdings Inc   38.76 %
Lite Strategy Inc   38.41 %
Enzo Biochem Inc  38.07 %
Northview Acquisition Corp  37.67 %
Mettler toledo International Inc   33.97 %
Semler Scientific inc   30.96 %
Escalon Medical Corp   30.94 %
Nrc Health  30.72 %
Vaso Corporation  29.37 %
Denali Therapeutics Inc   29.23 %
Shockwave Medical Inc   28.94 %
Arcturus Therapeutics Holdings Inc   28.09 %
Johnson and Johnson  25.57 %
Protalix Biotherapeutics inc   25.29 %
Tao Synergies Inc   24.90 %
Harmony Biosciences Holdings inc   23.56 %
Voyager Therapeutics Inc   23.09 %
Iradimed Corporation  21.83 %
Vertex Pharmaceuticals Inc  20.88 %
Pro dex Inc   20.79 %
Point Biopharma Global Inc   20.60 %
Tenax Therapeutics Inc   19.63 %
Bellicum Pharmaceuticals Inc   19.61 %

Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.